Myeloma expression systems

Journal of Immunological Methods

Volumn 261, Issue 1-2, 2002, Pages 1-20

  Yoo, Esther M ^a   Chintalacharuvu, Koteswara R ^a   Penichet, Manuel L ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody engineering; Monoclonal antibodies; Myeloma cells; Protein expression

Indexed keywords

ABCIXIMAB; CHIMERIC ANTIBODY; EDRECOLOMAB; HYBRID PROTEIN; IMMUNOGLOBULIN A; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; PALIVIZUMAB;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; CANCER CELL CULTURE; CARBOHYDRATE ANALYSIS; DIAGNOSTIC PROCEDURE; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GLYCOSYLATION; HUMAN; IMMUNOGENETICS; IMMUNOGLOBULIN PRODUCTION; IMMUNOGLOBULIN STRUCTURE; MOLECULAR BIOLOGY; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SECRETORY CELL; TECHNIQUE;

MURINAE;

EID: 0036499167     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-1759(01)00559-2     Document Type: Review

References (174)

1. Transporting therapeutics across the blood-brain barrier
2. Edrecolomab (monoclonal antibody 17-1A)
3. Mouse MHC class I-like Fc receptor encoded outside the MHC
4. A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes
5. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
6. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
7. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
8. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
9. In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells
10. Expression of engineered antibodies and antibody fragments in microorganisms
11. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
12. Production of functional chimaeric mouse/human antibody
13. Tight junctions of brain endothelium and epithelium
14. Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system
15. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
16. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor
17. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire
18. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region
19. Polymeric immunoglobulin M is secreted by transfectants of non-lymphoid cells in the absence of immunoglobulin J chain
20. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway
21. Molecular mechanisms of immunoglobulin A defense
22. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines
23. Residues critical for H-L disulfide bond formation in human IgA1 and IgA2
24. Production of secretory immunoglobulin A by a single mammalian cell
25. Disulfide bond formation between dimeric immunoglobulin A and the polymeric immunoglobulin receptor during hepatic transcytosis
26. Elimination of N-linked glycosylation sites from the human IgA1 constant region: Effects on structure and function
27. Humanized antibodies for therapy
28. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody
29. Clinical trials - Il-12 deaths - Explanation and a puzzle
30. The anti-GPIIb-IIIa agents: Fundamental and clinical aspects
31. Primer design for the cloning of immunoglobulin heavy-chain leader-variable regions from mouse hybridoma cells using the PCR
32. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction
33. Intravascular and mucosal immunoglobulin A: Two separate but related systems of immune defense?
34. Humanized monoclonal antibody CAMPATH-1H: Myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material
35. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies
36. Expression of an immunoglobulin heavy chain gene transfected into lymphocytes
37. IgA subclasses in various secretions and in serum
38. The liver in the IgA secretory immune system. Dogs, but not rats and rabbits, are suitable models for human studies
39. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity, cytokine function and demonstrates anti-tumor activity
40. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function
41. Biology of animal lectins
42. Blood-brain barrier transcytosis of insulin in developing rabbits
43. The binding site for C1q on IgG
44. Localization of the binding site for the human high-affinity Fc receptor on IgG
45. Glycobiology: Towards understanding the function of sugars
46. IgA nephropathy and related diseases
47. Receptor-mediated transcytosis of transferrin across the blood-brain barrier
48. Campath-1H monoclonal antibody therapy
49. Powerful and versatile enhancer-promoter unit for mammalian expression vectors
50. Preparation of monoclonal antibodies: Strategies and procedures
51. Specific amplification of rearranged immunoglobulin variable region genes from mouse hybridoma cells
52. Eukaryotic expression systems: A comparison
53. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice
54. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities
55. A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene
56. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes
57. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
58. Plasmid-encoded hygromycin B resistance: The sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae
59. Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces
60. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant
61. Two dominant-acting selectable markers for gene transfer studies in mammalian cells
62. Antibody phage display technology and its applications
63. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties
64. Immunoglobulin carbohydrate requirement for formation of an IgG-IgG complex
65. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
66. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn
67. Getting the glycosylation right: Implications for the biotechnology industry
68. Recombinant expression of polymeric IgA: Incorporation of J chain and secretory component of human origin
69. Role of J chain in secretory immunoglobulin formation
70. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor
71. IgA in blood and thoracic duct lymph: Concentration and degree of polymerization
72. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
73. Activity enhancement of a lung cancer-associated human monoclonal antibody HB4C5 by N-deglycosylation
74. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines
75. The structure and function of human IgA
76. Microbial evasion of IgA functions
77. Glycosylation at the Fab portion of myeloma immunoglobulin G and increased fucosylated biantennary sugar chains: Structural analysis by high-performance liquid chromatography and antibody-lectin enzyme immunoassay using Lens culinaris agglutinin
78. Assembly of asparagine-linked oligosaccharides
79. The coming of age of the immunoglobulin J chain
80. Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation
81. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation
82. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction
83. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: Implications for maternal-fetal antibody transport
84. Effector functions of a monoclonal aglycosylated mouse IgG2a: Binding and activation of complement component C1 and interaction with human monocyte Fc receptor
85. Use of rituximab, the new FDA-approved antibody
86. Structural characterization of the oligosaccharides of a human monoclonal anti-lipopolysaccharide immunoglobulin M
87. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions
88. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins
89. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies
90. Control of IgG/Fc glycosylation: A comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs
91. Interleukin-2 in cancer treatment: Disappointing or (still) promising?
92. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein
93. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions
94. A three-tiered view of the role of IgA in mucosal defense
95. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody
96. Human and murine immunoglobulin expression vector cassettes
97. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
98. Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response
99. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin
100. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G
101. Characterization of the glycosylation of a human IgM produced by a human-mouse hybridoma
102. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding
103. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains
104. Transepithelial transport of immunoglobulins
105. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase
106. Reduction of acute renal allograft rejection by daclizumab
107. Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells
108. Recombinant antibodies possessing novel effector functions
109. A hapten-specific chimeric IgE antibody with human physiological effector function
110. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells
111. Biological significance of carbohydrate chains on monoclonal antibodies
112. Immunoglobulin gene expression in transformed lymphoid cells
113. Concepts and principles of glycobiology
114. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction
115. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells
116. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG
117. Rheumatoid arthritis as a glycosylation disorder
118. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity
119. Antibody-cytokine fusion proteins for the therapy of cancer
120. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity
121. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain
122. Fab fusion proteins: Immunoligands
123. Molecular cloning of the mouse polymeric Ig receptor. Functional regions of the molecule are conserved among five mammalian species
124. Infliximab for the treatment of fistulas in patients with Crohn's disease
125. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide
126. The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis
127. Agalactosyl glycoforms of IgG autoantibodies are pathogenic
128. Reshaping human antibodies for therapy
129. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes
130. Kinetics of recombinant immunoglobulin production by mammalian cells in continuous culture
131. Optimization of a fed-batch process for production of a recombinant antibody
132. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
133. Demonstration and structural comparison of receptors for insulin-like growth factor-I and -II (IGF-I and -II) in brain and blood-brain barrier
134. Diversification of the IgG molecule by oligosaccharides
135. Granulocyte-macrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness
136. Biological activities of IgA
137. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen
138. Principles of brain tumor chemotherapy
139. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal alpha-linked galactose
140. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R
141. Functional properties of antibody insulin-like growth factor fusion proteins
142. Transferrin-antibody fusion proteins are effective in brain targeting
143. A better cell line for making hybridomas secreting specific antibodies
144. Interleukin-2 toxicity
145. An Fc receptor structurally related to MHC class I antigens
146. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
147. Recombinant polymeric IgG: An approach to engineering more potent antibodies
148. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4
149. Nuclear and cytoplasmic glycosylation
150. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex
151. Structural requirements for incorporation of J chain into human IgM and IgA
152. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter
153. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection
154. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus
155. Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A
156. Generation of specificity-variant antibodies by alteration of carbohydrate in light chain of human monoclonal antibodies
157. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
158. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation
159. Selective removal of alpha heavy-chain glycosylation sites causes immunoglobulin A degradation and reduced secretion
160. Characteristics of an immune system common to certain external secretions
161. IL-12 induces T helper 1-directed antitumor response
162. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
163. The use of antibodies against the IL-2 receptor in transplantation
164. Glycosylation of a VH residue of a monoclonal antibody against alpha (1 → 6) dextran increases its affinity for antigen
165. Analysis of carbohydrates on IgG preparations
166. Appropriate mammalian expression systems for biopharmaceuticals
167. Transformation of mammalian cells with an amplifiable dominant-acting gene
168. High level synthesis of immunoglobulins in Chinese hamster ovary cells
169. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells
170. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy
171. T cell memory against colon carcinoma is long-lived in the absence of antigen
172. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement
173. Structural requirements for polymeric immunoglobulin assembly and association with J chain
174. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells